Lexaria Bioscience’s Treasury‑Return Move Signals Strategic Confidence for Investors
Lexaria Bioscience’s zero‑price insider share return signals strategic balance‑sheet control, positioning the biotech for future capital raises and market‑access wins while boosting investor confidence.
4 minutes to read